Posts

Posted on

Cano Health Announces the Formation of its Board of Directors

Newly-formed Board of Directors comprised of a diverse bench of experts to drive Company’s growth

PR Newswire

MIAMI, March 15, 2021 /PRNewswire/ — Cano Health (the “Company”), a leading value-based primary care delivery platform for seniors, today announced the formation of its Board of Directors, consisting of seasoned professionals from across the health care, technology and financial sectors.

Upon the closing of the business combination with Jaws Acquisition Corp. (NYSE: JWS), the members of the Board of Directors will include Dr. Marlow Hernandez, Founder and CEO of Cano Health, alongside Elliot Cooperstone, Dr. Lewis Gold, Jacqueline Guichelaar, Angel Morales, Dr. Alan Muney, Kim Rivera, Barry Sternlicht, and Solomon Trujillo. Dr. Marlow Hernandez will serve as Chairman of the Board.

“I am pleased to welcome the members of our newly-formed Board of Directors. As Cano Health prepares for its next stage of growth as a publicly-traded company, the Board’s diverse experience and strategic expertise will be an invaluable asset to our management team,” said Dr. Hernandez. “I am humbled and honored to partner with this outstanding group of professionals to continue to transform healthcare in America.”


Marlow Hernandez

Dr. Marlow Hernandez is the Founder and Chief Executive Officer of Cano Health and will serve as the Chairman of its Board of Directors. A native of Cuba, Dr. Hernandez immigrated to the U.S. with his family in 1993. Driven by a lifelong calling to medicine, he received a bachelor’s degree in neuroscience from the University of Miami, a medical degree from Nova Southeastern University, and completed his residency in internal medicine at Cleveland Clinic Florida. He also received master’s degrees in business administration and public health, and is a fellow of the American College of Physicians. Dr. Hernandez opened his first medical center in 2010. He saw a need in his community for quality, affordable healthcare, and developed an integrated primary care model focused on improving clinical outcomes and decreasing costs. From humble beginnings as a small practice in Pembroke Pines, Florida, Cano Health has grown to more than 70 medical centers across Florida, Texas, and Nevada serving over 100,000 managed care patients. 


Elliot Cooperstone

Mr. Cooperstone is the Founder and Managing Partner of InTandem Capital Partners, a leading private equity firm that invests in and accelerates the growth of small to mid-sized companies in select health care and insurance services sectors. Mr. Cooperstone was previously CEO of Prodigy Health Group, a health care services holding company acquired in 2011 by Aetna. Earlier in his career, Mr. Cooperstone was General Manager of the Employer Services Group at Intuit, a co-founder and CEO of EmployeeMatters, and Executive Vice President and Chief Administrative Officer of Alexander & Alexander Services, Inc.  He also had prior experience with Travelers Group, The Walt Disney Company and The Boston Consulting Group.  


Lewis Gold

Dr. Gold is Co-Founder and Chairman of the Board at Advanced Recovery Systems, an integrated behavioral health company specializing in the treatment of substance abuse, eating disorders and associated mental health issues. He also serves as non-executive Chairman of Urology Management Associates and Siromed. Previously, Dr. Gold co-founded Sheridan Healthcare in 1994 and served as its Executive Vice Chairman and on its Board of Directors. Under his leadership, Sheridan Healthcare grew from a single local practice to a national company in 23 states.  


Jacqueline Guichelaar

Ms. Guichelaar is Senior Vice President and Group Chief Information Officer at Cisco Systems, Inc. (“Cisco”), where she oversees a multi-billion-dollar organization responsible for transforming all of Cisco’s business processes, underpinned by technology platforms and a clear data strategy, with the ultimate goal of maximizing the customer, partner and employee experience. Prior to joining Cisco, she was the Group Chief Information Officer at Thomson Reuters, where she led a technology organization to deliver the company’s digital strategy. Throughout her career, including roles at Lloyds Bank, Deutsche Bank, and IBM, Ms. Guichelaar has focused on the transformation of companies by creating teams that move in tandem with business expectations and the pace of the industry.  She is a board member of Covenant House in California, a non-profit that believes all young people deserve food, shelter, clothing, education, and love.


Angel Morales

Mr. Morales is the Founder and CEO of Morales Capital, an investment firm focused on private equity opportunities in mission-oriented companies managed by Latinos and other underrepresented groups. He has 25 years of private equity experience, including as co-head of Bank of America Merrill Lynch Capital Partners and as a co-Founder and Managing Partner of North Cove Partners, an investment management firm with a global portfolio and assets under management in excess of $6 billion. He has served on the Board of Directors for a number of public and private companies in the United States and abroad. Mr. Morales is active in education-related philanthropy and serves as the Founding Board Chair of Comp Sci High in the South Bronx as well as on the Board of Directors of the Hispanic Scholarship Fund and Transcend Education.


Alan Muney

Dr. Muney is currently a senior healthcare advisor for several private investment funds and serves on the Board of Directors for both Alcresta Therapeutics and KabaFusion. Previously, he served as Cigna’s Chief Medical Officer, responsible for clinical strategy and policy, health advocacy programs, coverage policy, and quality measurement and improvement, and as the Executive Vice President of Total Health and Network, responsible for internal and external clinical operations and nationally for provider contracting and provider relations. Prior to Cigna, Dr. Muney was an Executive Director in the Private Equity Group at The Blackstone Group, and the CEO of Equity Healthcare, which he founded to manage the healthcare costs of Blackstone’s portfolio companies. He previously served as Executive Vice President and Chief Medical Officer of Oxford Health Plans, Chief Medical Officer of UnitedHealthcare’s Northeast region, Senior Vice President and Chief Medical Officer for Avanti Health systems, and Regional Medical Director for Mullikin Medical Centers in California.


Kim Rivera

Ms. Rivera currently serves as a special advisor to the CEO of HP, Inc. She is a seasoned public company executive with a track record spanning technology, health care, and consumer products. She has experience shaping and driving business and go-to-market strategies, negotiating and integrating major acquisitions, and navigating complex corporate governance, compliance and regulatory issues. Most recently, she was President, Strategy and Business Management and Chief Legal Officer at HP. During her tenure in this role she led corporate strategy and business development, customer support, procurement, real estate and workplace functions, as well as sales operations and enterprise transformation. Ms. Rivera also led HP’s worldwide legal organization, including all aspects of legal, governance, ethics and compliance, and government affairs. Prior to joining HP, she served as the Chief Legal Officer and Corporate Secretary for DaVita HealthCare Partners. Ms. Rivera also held senior executive legal and compliance positions at The Clorox Company and Rockwell Automation. Ms. Rivera serves on the Thomson Reuters Board of Directors, and is a member of their Audit and Risk Committees.


Barry Sternlicht

Mr. Sternlicht is the Chairman of Jaws Acquisition Corp. Mr. Sternlicht founded Starwood Capital, a private alternative investment firm focused on global real estate, hotel management, and energy infrastructure, in 1991, serving as Chairman and Chief Executive Officer. Mr. Sternlicht currently serves as the Chairman and Chief Executive Officer of Starwood Property Trust (NYSE: STWD), a leading, diversified real estate finance company. Mr. Sternlicht also has deep operating expertise, serving as the Chairman, from January 1995 through May 2005, and as the Chief Executive Officer, from January 1995 through September 2004, of Starwood Hotels & Resorts Worldwide. Some of Mr. Sternlicht’s other public market experience includes serving as a Director of INVH, the largest publicly-traded investor, owner and operator of single-family homes in the U.S.; serving on the Board of Directors of The Estée Lauder Companies, a multinational manufacturer and marketer of prestige skincare, makeup, fragrance and hair care products, since 2004; and serving as a Director of A.S. Roma, the professional Italian football club based in Rome, from 2014-2020.


Solomon Trujillo

Mr. Trujillo is a global business executive who has uniquely served as CEO of three large market-cap global companies in the three corridors of the world. He is known as a transformative and innovative leader, recognized for his technology and innovation leadership in communications, media, and technology. Mr. Trujillo has served on the Board of Directors of globally branded companies including PepsiCo, Bank of America, EDS, Orange, Telstra, Gannett, US West, Target, Soufun (China), and WPP. He currently serves on the Board of Directors of Western Union, a global financial services company, and Encantos, an award-winning ed-tech company. He served as a trade policy advisor to the Clinton and Bush administrations and remains active in public policy issues related to trade, productivity, innovation, and economic development. Mr. Trujillo chairs the Trujillo Group, LLC, investing in private companies domestically and internationally. 

About Cano Health

Cano Health operates value-based primary care centers and supports affiliated medical practices that specialize in primary care for seniors in Florida, Texas, Nevada, and Puerto Rico, with additional markets in development. As part of its care coordination strategy, Cano Health provides sophisticated, high-touch population health management tools including telehealth, prescription home delivery, wellness programs, transition of care, and high-risk and complex care management.

The Company’s personalized patient care and proactive approach to wellness and preventive care sets it apart from competitors. Cano Health has consistently improved clinical outcomes while reducing costs, affording patients the opportunity to lead longer and healthier lives. The Company was recognized in August 2020 by Inc. Magazine for the second consecutive year as one of the fastest-growing health care companies in the country, ranking 39th among all U.S. privately held companies as part of its annual 5000 ranking. For more information visit www.canohealth.com.

Additional Information

On November 11, 2020, Jaws Acquisition Corp. (“Jaws”) entered into a business combination agreement (as it may be amended, supplemented or otherwise modified from time to time, the “Business Combination Agreement” and the transactions contemplated therein, the “Business Combination”), by and among Jaws, Jaws Merger Sub, LLC, Primary Care (ITC) Holdings, LLC and the Company.

In connection with the Business Combination, including the domestication of Jaws as a Delaware corporation, Jaws filed with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 containing a preliminary proxy statement and a preliminary prospectus of Jaws, and after the registration statement is declared effective, Jaws will mail a definitive proxy statement/prospectus about the Business Combination to its shareholders. This Current Report on Form 8-K does not contain all the information that should be considered concerning the Business Combination and is not intended to form the basis of any investment decision or any other decision in respect of the Business Combination. Jaws’ shareholders and other interested persons are advised to read the preliminary proxy statement/prospectus and, when available, any amendments thereto, the definitive proxy statement/prospectus and other documents filed in connection with the Business Combination, as these materials will contain important information about Jaws, the Company and the Business Combination. When available, the definitive proxy statement/prospectus and other relevant materials for the Business Combination will be mailed to shareholders of Jaws as of the record date that was established for voting on the Business Combination. Shareholders are able to obtain copies of the preliminary proxy statement/prospectus and, once available, the definitive proxy statement/prospectus and other documents filed with the SEC, without charge, at the SEC’s website at www.sec.gov, or by directing a request to: 1601 Washington Avenue, Suite 800, Miami Beach, FL 33139.

Participants in the Solicitation

Jaws and its directors and executive officers may be deemed participants in the solicitation of proxies from Jaws’ shareholders with respect to the Business Combination. A list of the names of those directors and executive officers and a description of their interests in Jaws is contained in Jaws’ final prospectus related to its initial public offering, dated April 28, 2020, which was filed with the SEC and is available free of charge at the SEC’s website at www.sec.gov, or by directing a request to Jaws Acquisition Corp., 1601 Washington Avenue, Suite 800, Miami Beach, FL 33139. Additional information regarding the interests of such participants will be contained in the definitive proxy statement/prospectus for the Business Combination when available.

The Company and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of Jaws in connection with the Business Combination. A list of the names of such directors and executive officers and information regarding their interests in the Business Combination will be included in the definitive proxy statement/prospectus for the Business Combination when available.

No Offer or Solicitation

This communication is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Jaws or the Company, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act.

Forward-Looking Statements

Certain statements in this Current Report on Form 8-K may be considered forward-looking statements. Forward-looking statements generally relate to future events or Jaws’ or the Company’s future financial or operating performance. For example, projections of future growth, financial performance, and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “potential” or “continue,” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements.

These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Jaws and its management, and the Company and its management, as the case may be, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of negotiations and any subsequent definitive agreements with respect to the Business Combination; (2) the outcome of any legal proceedings that may be instituted against Jaws, the combined company or others following the announcement of the Business Combination and any definitive agreements with respect thereto; (3) the inability to complete the Business Combination due to the failure to obtain approval of the shareholders of Jaws, to obtain financing to complete the Business Combination or to satisfy other conditions to closing; (4) changes to the proposed structure of the Business Combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination; (5) the ability to meet stock exchange listing standards following the consummation of the Business Combination; (6) the risk that the Business Combination disrupts current plans and operations of the Company as a result of the announcement and consummation of the Business Combination; (7) the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (8) costs related to the Business Combination; (9) changes in applicable laws or regulations; (10) the possibility that the Company or the combined company may be adversely affected by other economic, business, and/or competitive factors; (11) the Company’s estimates of expenses and profitability; and (12) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in Jaws’ final prospectus relating to its initial public offering, dated April 28, 2020.

Nothing in this Current Report on Form 8-K should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Neither Jaws nor the Company undertakes any duty to update these forward-looking statements.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cano-health-announces-the-formation-of-its-board-of-directors-301247363.html

SOURCE Cano Health, LLC

Posted on

University of Minnesota Medical School launches clinical trial studying metformin treatment for COVID-19

The multi-site clinical trial is currently seeking volunteers for the outpatient study

Minneapolis / St. Paul, March 15, 2021 (GLOBE NEWSWIRE) — A new multi-site clinical trial led by the University of Minnesota Medical School is studying the effectiveness of metformin, a generic medication for type 2 diabetes, in the treatment of COVID-19. It will be the first randomized clinical trial for COVID-19 in the world to include pregnant women.

The clinical trial launched after U of M Medical School researchers identified in computer modeling and observational studies that outpatient metformin use may decrease the likelihood of dying from or being hospitalized for COVID-19. Their research was published in the Journal of Medical Virology and in The Lancet Healthy Longevity, which was in partnership with UnitedHealth Group’s OptumLabs.

“Observational studies like this cannot be conclusive but do contribute to growing bodies of evidence,” said Carolyn Bramante, MD, principal investigator of the study and an assistant professor of internal medicine and pediatrics at the U of M Medical School. “To complete this study, we are currently enrolling volunteers through six institutions in the U.S., including in Minneapolis.” 

The study is simple — patients receive 14 days’ worth of immediate-release metformin or a placebo to take twice per day and track their symptoms. After the 14 days, volunteers complete a survey.

Volunteers for the trial should be between the ages of 30 and 85 years old with a body mass index greater than or equal to 25kg/m2, or someone who is at least five feet and six inches tall and weighs more than 155 pounds. To qualify for the study, volunteers must enroll within three days after receiving a positive COVID-19 test.

“Some new strains of the virus may evade immunity from some of the vaccines. Additionally, worldwide vaccine availability will take time, and not all individuals may get the vaccine. Thus, we need safe, available, inexpensive outpatient treatment options as soon as possible,” said Bramante, who is also an internist and pediatrician with M Health Fairview. “Having a realistic outpatient treatment option will ensure more people survive the illness if they contract it.”

Funding and support for stage one of the multi-site trial comes from the Parsemus Foundation, a private foundation in San Francisco, and OptumLabs.

“I am excited to participate in this study,” said Ken Cohen, MD, FACP, executive director of Translational Research, OptumLabs and co-investigator of the study. “Finding an effective, safe, low-cost medication that could treat COVID-19 worldwide, particularly in countries with low healthcare resources, is a critically important endeavor.”

Participating clinical trial sites include M Health Fairview and Hennepin Healthcare in Minneapolis, Northwestern University in Chicago, Olive View – UCLA Education & Research Institute in Los Angeles, Optum in Colorado and Indiana and University of Colorado Denver. Co-investigators on the study include Hrishikesh Belani, MD; David Boulware, MD; David Leibovitz, MD; Jacinda Nicklas, MD; Mike Puskarich, MD; and Christopher Tignanelli, MD.

In the near future, this clinical trial plans to expand to include the study of two other promising drugs, which has been supported by two additional funding partners. This expansion of the clinical trial is pending both FDA and IRB approval before it can launch.

To learn more about how to qualify for this study, visit https://covidout.com. 

###

About the University of Minnesota Medical School

The University of Minnesota Medical School is at the forefront of learning and discovery, transforming medical care and educating the next generation of physicians. Our graduates and faculty produce high-impact biomedical research and advance the practice of medicine. Visit med.umn.edu to learn how the University of Minnesota is innovating all aspects of medicine.

Attachment 



Angel Mendez
University of Minnesota Medical School
785-741-5267
[email protected]

Posted on

Numinus Wellness Inc. Announces Upsized Bought Deal Public Offering to $35 million

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

VANCOUVER, British Columbia, March 15, 2021 (GLOBE NEWSWIRE) — Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, is pleased to announce that it has entered into a revised agreement with Eight Capital and Canaccord Genuity Corp. (the “Underwriters”). The Underwriters have now agreed to purchase, on a bought deal basis pursuant to the filing of a prospectus supplement to the Company’s short form base shelf prospectus dated March 12, 2021, an aggregate of 28,000,000 units (the “Units”) at a price of $1.25 per Unit (the “Offering Price”) for aggregate gross proceeds to the Company of $35 million (the “Offering”).

Each Unit shall consist of one common share (each a “Common Share”) and one-half of one common share purchase warrant of the Company (each a “Warrant”). Each Warrant shall be exercisable to acquire one common share of the Company for a period of 24 months from closing of the Offering at an exercise price of $1.75 per Warrant.

The Company has granted the Underwriters an option (the “Over-Allotment Option”) to purchase up to an additional 4,200,000 Units at the Offering Price per Unit, exercisable at any time, for a period of 30 days after and including the Closing Date (as defined herein), which would result in additional proceeds of up to $5.25 million. The Over-Allotment Option is exercisable to acquire Units, Common Shares and/or Warrants (or any combination thereof) at the discretion of the Underwriters.

The Units will be offered by way of a prospectus supplement to the Company’s short form base shelf prospectus to be filed in all provinces and territories of Canada except Quebec. The Units may also be offered in the United States on a private placement basis pursuant to applicable exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the “1933 Act”) and applicable state securities laws, and in other offshore jurisdictions provided that no prospectus filing or comparable obligation arises. The Offering is expected to close on March 18, 2021 (the “Closing Date”) and is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the TSX Venture Exchange (“TSXV”) and the applicable securities regulatory authorities.

The Company will use best efforts to obtain the necessary approvals to list the Common Shares, Warrants, and the Common Shares issuable upon exercise of the Warrants on the TSXV.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the 1933 Act and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements of the 1933 Act, and applicable state securities laws.

Numinus intends to use the proceeds of the Offering for working capital and general corporate purposes.

ON BEHALF OF THE BOARD OF NUMINUS WELLNESS INC.
Payton Nyquvest
President, Chief Executive Officer and Chair

About Numinus

Numinus Wellness Inc. (TSXV: NUMI) is a mental health and wellness company creating an ecosystem of solutions centred around safe, evidence-based, accessible psychedelic-assisted psychotherapy to help people heal and be well.

Numinus Health is dedicated to delivering innovative treatments to address physical, mental, and emotional health, through clinics and virtual services.

Numinus R&D is conducting implementation science and leveraging partnerships to beta-test and refine optimal models of psychedelic-assisted psychotherapy delivery, setting the stage for approved routine use in mental health and wellness care.

Numinus Bioscience is focused on developing testing methods and effective formulas for the evolving psychedelics space. Health Canada licences, scientific expertise, and new technologies facilitate ongoing innovation, and high-throughput contract services generate established revenue.

Learn more at numinus.ca, and follow us on Facebook, Twitter, and Instagram.


Forward Looking Statements

This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licences and any inability to obtain all necessary governmental approvals licences and permits to operate and expand the Company’s facilities; regulatory or political change such as changes in applicable laws and regulations, including federal and provincial legalization, due to inconsistent public opinion, perception of the integrative mental health industry, including the use of psychedelic-assisted therapies, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; the Company’s limited operating history and lack of historical profits; reliance on management; the Company’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with research and development institutions, customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law. SOURCE Numinus Wellness Inc.

For media inquiries and further information:

May Lee, Communications Manager, Numinus,

[email protected]

.



Posted on

IIROC Trading Halt – GGG

Canada NewsWire

VANCOUVER, BC, March 15, 2021 /CNW/ – The following issues have been halted by IIROC:

Company: G6 Materials Corp.

TSX-Venture Symbol: GGG

All Issues: Yes

Reason: At the Request of the Company Pending News

Halt Time (ET): 9:40 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

Posted on

IIROC Trading Resumption – GLDX

Canada NewsWire

VANCOUVER, BC, March 15, 2021 /CNW/ – Trading resumes in:

Company: Gold X Mining Corp.

TSX-Venture Symbol: GLDX

All Issues: No

Resumption (ET): 9:45 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

Posted on

(STAY Alert) Johnson Fistel Investigates Proposed Sale of Extended Stay; Are Shareholders Getting a Fair Deal?

PR Newswire

SAN DIEGO, March 15, 2021 /PRNewswire/ — Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Extended Stay America, Inc., (NASDAQ: STAY) breached their fiduciary duties in connection with the proposed sale of the Company to Blackstone Real Estate Partners (“Blackstone”) and Starwood Capital Group (“Starwood Capital”).  

On March 15, 2021, Extended Stay announced that it had entered into a definitive merger agreement with Blackstone and Starwood Capital. Under the terms of the definitive merger agreement, Blackstone and Starwood Capital will acquire all of the issued and outstanding shares of Extended Stay common stock for $19.50 per share in cash.

The investigation concerns whether the Extended Stay board failed to satisfy its duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for Extended Stay shares of common stock. Nationally recognized Johnson Fistel is investigating whether the proposed deal represents adequate consideration, especially given analysts’ projections for future revenue growth.

If you are a shareholder of
Extended Stay
 and believe the proposed buyout price is too low or you’re interested in learning more about the investigation, please contact lead analyst Jim Baker ([email protected]) at 619-814-4471. If emailing, please include a phone number.

Additionally, you can [Click here to join this action]. There is no cost or obligation to you.

About Johnson Fistel, LLP:

Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit https://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:

Johnson Fistel, LLP
Jim Baker, 619-814-4471
[email protected]

[Click here to join this action]

Cision View original content:http://www.prnewswire.com/news-releases/stay-alert-johnson-fistel-investigates-proposed-sale-of-extended-stay-are-shareholders-getting-a-fair-deal-301247352.html

SOURCE Johnson Fistel, LLP

Posted on

Swapalease.com Releases Latest Figures on Lease Credit Approvals Showing Slight Increase for February

Lease Credit Approvals Reached 70.8% in February; Up Slightly from 68% in January

CINCINNATI, Ohio, March 15, 2021 (GLOBE NEWSWIRE) — Swapalease.com, the nation’s largest car lease marketplace, reports car lease credit applicants registered a 70.8% approval rate in February. The approval rate is a slight increase from the 68.3% approval mark that opened up the new year in January.

The February number is just off slightly from the same time last year, when the approval rate was at 72.3% right before the beginning of the pandemic. The steady numbers indicate consumer credit levels are also holding steady, perhaps as a continued sign of the ongoing stimulus relief provided by the government.

According to recent Federal Reserve data, consumer borrowing decelerated again in January, which may suggest that Americans are using the latest stimulus checks to pay down debt. Total consumer credit decreased $1.3 billion In January, the Fed said. That’s an annual decline at a 0.4% rate and follows a 2.5% gain in the prior month.

Swapalease.com believes many of its site visitors and vehicle shoppers have solid credentials available to take over a person’s vehicle lease. The inclination to have more flexibility through leasing amidst economic uncertainly may contribute to a rise in shoppers who are looking to lease vehicles through the secondary market, where lease payments are more attractive than what is currently offered at the dealership.

“Given that the year has started out with credit-stability figures that were maintained throughout the third and fourth quarters, we believe in the short term this stability will continue,” said Scot Hall, Executive Vice President of Swapalease.com. “The latest and recently signed stimulus package, combined with the accelerated momentum we’re seeing with vaccine rollouts should further strengthen the outlook for credit in the months ahead.”

Swapalease.com matches a person wanting out of their existing vehicle lease contract with a car shopper looking to take over a short-term vehicle lease. The marketplace has thousands of cars and trucks available for transfer to anywhere in the continental U.S.

About Swapalease.com:

Headquartered in Cincinnati, Ohio, Swapalease.com is the world’s largest automotive lease marketplace and the pioneer in facilitating lease transfers online. More specifically Swapalease.com matches individuals who want to get out of their lease with people who are looking for short-term lease agreements. Prospective buyers can search the listings for the exact vehicle they want, and then register for a nominal fee, allowing them to use Swapalease.com’s safe online system to contact the prospective seller and close the deal. For more information about Swapalease.com or how to exit your lease early, call 866-SWAPNOW or visit www.swapalease.com.

Press Contact:  
Sarah Caro
Merit Mile  
[email protected]  
O – 561-362-8888  
C – 863-599-0109

 



Posted on

Konica Minolta Celebrates International Women’s Day 2021

Company Empowers Employees Across the Globe to Create a More Equal Workplace

Ramsey, NJ, March 15, 2021 (GLOBE NEWSWIRE) — Konica Business Solutions U.S.A., Inc. (Konica Minolta) aims to be an organization where diverse individuals can thrive and make an impact with our customer partners and in the communities we serve. In support of International Women’s Day (IWD), the company today announced its efforts to celebrate the achievements of women across its organization. IWD is a global celebration of women’s social, economic, cultural and political accomplishments, which closely aligns with Konica Minolta’s vision to inspire, engage and grow all employees to reach their full potential.

Konica Minolta has been supporting IWD in various countries for several years, and for 2021 created a more cohesive and iconic event for its employees. The company hosted a global panel discussion reflecting IWD’s themes of equity, inclusion, and empowerment, featuring the following women from Konica Minolta offices around the world:

Elena Drecheva – Managing Director, Konica Minolta Bulgaria

Ciara Finucane – Vice President, Discovery & Preclinical Services, Invicro (a Konica Minolta company)

Joy Lynn – General Manager, Marketing Division, Konica Minolta Business Solutions (China) Co., Ltd

Vicky Ringwood – Senior Vice President, Human Resources, Konica Minolta Business Solutions, U.S.A., Inc.

The event included a special message from Shoei Yamana, President and CEO at Konica Minolta Inc., in which he mentioned the importance of empathy in fostering a culture of inclusion and belonging. The panel discussion revolved around the importance of a diverse workforce to the future of Konica Minolta and the tech industry, and the role all employees play in challenging the status quo to achieve gender equality. Amidst the backdrop of a global pandemic and social unrest in America, the panel signaled the importance of united and inclusive leadership now more than ever. The session was attended by more than 600 employees across 29 countries.

“At Konica Minolta, we strive to attract diverse talent by fostering a culture of innovation and success where employees feel they can contribute, grow and thrive, said Vicky Ringwood, Senior Vice President, Human Resources, Konica Minolta. “That’s why it’s critically important to address the policies, processes and programs that underpin the employee journey, from interviewing and hiring, to onboarding and development.”

Konica Minolta showcased more thought leadership through a robust social media campaign, which featured some of the following insights from female employees.

  • “It’s critical that we are intentional about the experiences that we create for our workforce to ensure that everyone feels seen and heard. I believe we can challenge biases to promote inclusion and belonging through education, engagement, honoring our own truths and creating safe and brave spaces to learn, connect, and grow.” – Jelandré Hopson, Admin Ops Specialist
  • “If employees feel we have their best interest at heart, they will work to help find solutions to increase the team’s performance. It becomes part of the culture where employees hold each other accountable. Individual accomplishments are nice, but when the team succeeds everyone WINS.” – Dana Drury, Area Vice President
  • “At Konica Minolta, I have had the pleasure of working for both female and male leadership who have taken notice of my abilities and strengths, providing me with the opportunities to grow, and the support needed to succeed.” – Karla Polanco, Region Planning Director
  • “I feel very lucky that over my 4.5 years with Konica Minolta I’ve had a manager who champions an inclusive work culture, where no matter what your title is your voice is valid, and no idea is dismissed. This wonderful environment coupled with mentors and allies across the business means I now have a great network of colleagues I can rely on for support, and leaves me feeling empowered to continue to push myself and reach my goals.” – Becca Cross, Brand Communications Manager

In support of empowering women and in alignment with its mission to help companies achieve their goals through better management of information and more effective collaboration through its IT Services Division, All Covered, Konica Minolta also made a significant donation to Girls Who Code. Girls Who Code is an international non-profit organization working to close the gender gap in technology and change the image of what a programmer looks like and does. The contribution will help support efforts to inspire, educate, and equip girls with computing skills to become change agents in their communities.

Watch clips from Konica Minolta’s global leadership panel online.

About Konica Minolta

Konica Minolta Business Solutions U.S.A., Inc. is reshaping and revolutionizing the Workplace of the Future™. The company guides and supports its customers’ digital transformation through its expansive office technology portfolio, including IT Services (All Covered), ECM, managed print services and industrial and commercial print solutions. Konica Minolta has been included on CRN’s MSP 500 list nine times and The World Technology Awards recently named the company a finalist in the IT Software category. Konica Minolta has been recognized as the #1 Brand for Customer Loyalty in the MFP Office Copier Market by Brand Keys for fourteen consecutive years, and received Keypoint Intelligence’s BLI 2021 A3 Line of The Year Award and BLI 2021-2023 Most Color Consistent A3 Brand Award for its bizhub i-Series. Konica Minolta, Inc. has been named to the Dow Jones Sustainability World Index for nine consecutive years and has spent four years on the Global 100 Most Sustainable Corporations in the World list. Konica Minolta partners with its clients to give shape to ideas and work to bring value to our society. For more information, please visit us online and follow Konica Minolta on Facebook,  YouTube, LinkedIn  and Twitter.

About Konica Minolta Business Solutions (Canada) Ltd.

Konica Minolta Business Solutions (Canada) Ltd. is reshaping and revolutionizing the Workplace of the Future™. With our comprehensive portfolio, we deliver solutions to leverage mobility and cloud services and optimize business processes with workflow automation. Konica Minolta’s IT Services Division offers a range of IT strategy, support and network security solutions across all verticals. Konica Minolta has been recognized by Brand Keys as the #1 Brand for Customer Loyalty in the MFP Office Copier market for 13 consecutive years. Konica Minolta, Inc. has been named to the Dow Jones Sustainability World Index for eight years in a row. We partner with our customers to give shape to ideas and work to bring value to our society. For more information, please visit www.konicaminolta.ca and follow Konica Minolta on LinkedIn, YouTube, Facebook and Twitter (@KonicaMinoltaCA).

Konica Minolta Business Solutions (Canada) Ltd. Press Contact
Konica Minolta Media Relations – Canada
[email protected]

 

# # # # #

Attachment 



Maggie Grande
Konica Minolta Business Solutions U.S.A., Inc.
1-551-500-2659
[email protected]

Posted on

XL SHAREHOLDER DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against XL Fleet Corp.

NEW YORK, March 15, 2021 (GLOBE NEWSWIRE) — Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of XL Fleet Corp. (“XL Fleet” or the “Company”) (NYSE: XL) from October 2, 2020 through March 2, 2021 (the “Class Period”). The lawsuit filed in the United States District Court for the Southern District of New York alleges violations of the Securities Exchange Act of 1934.

If you purchased XL Fleet securities, and/or would like to discuss your legal rights and options please visit XL Fleet Shareholder Class Action Lawsuit or contact Matthew E. Guarnero toll free at (877) 779-1414 or [email protected]

The complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose to investors: (i) that XL Fleet’s salespeople were pressured to inflate their sales pipelines to boost the Company’s reported sales and backlog; (ii) that at least 18 of 33 customers that XL featured were inactive and had not placed an order since 2019; (iii) that XL’s technology had been materially overstated and offered only 5% to 10% of fleet savings; (iv) that XL lacks the supply chain and engineers to roll out new products on the announced timelines; and (v) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On March 3, 2021, Muddy Waters Research (“Muddy Waters”) published a report entitled: “XL Fleet Corp. (NYSE: XL): More SPAC Trash,” alleging, among other things, that salespeople were “pressured to inflate their sales pipelines materially in order to mislead XL’s board and investors” and that “customer reorder rates are in reality quite low” due to “poor performance and regulatory issues.” Citing interviews with former employees, the report alleged that “at least 18 of 33 customers XL featured were inactive.” Muddy Waters also claimed that XL has “weak technology” and that “XL’s announcement of future class 7-8 upfits seems highly promotional” because the task is “too technologically complex for XL engineers to deliver on the promised timeline.”

On this news, the Company’s share price fell $2.09, or 13%, to close at $13.86 per share on March 3, 2021, on unusually heavy trading volume. The share price continued to decline by $2.69, or 19.4%, over two consecutive trading sessions to close at $11.17 per share on March 5, 2021, on unusually heavy trading volume.

If you wish to serve as lead plaintiff, you must move the Court no later than May 7, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

If you purchased XL Fleet securities, and/or would like to discuss your legal rights and options please visit https://www.bernlieb.com/cases/xlfleetcorp-xl-shareholder-class-action-lawsuit-fraud-stock-377/apply/ or contact Matthew E. Guarnero toll free at (877) 779-1414 or [email protected].

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2021 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information

Matthew E. Guarnero
Bernstein Liebhard LLP
https://www.bernlieb.com
(877) 779-1414
[email protected]



Posted on

WKHS SHAREHOLDER DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion In a Securities Class Action Lawsuit Against Workhorse Group, Inc.

NEW YORK, March 15, 2021 (GLOBE NEWSWIRE) — Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Workhorse Group, Inc. (“Workhorse Group” or the “Company”) (NASDAQ: WKHS) from July 7, 2020 through February 23, 2021 (the “Class Period”). The lawsuit filed in the United States District Court for the Central District of California alleges violations of the Securities Exchange Act of 1934.

If you purchased Workhorse Group securities, and/or would like to discuss your legal rights and options please visit Workhorse Group Shareholder Class Action Lawsuit or contact Matthew E. Guarnero toll free at (877) 779-1414 or [email protected]

In 2016, the United States Postal Service (“USPS”) launched the USPS Next Generation Delivery Vehicle (“NGDV”) project, which was a competitive multiyear acquisition process to replace approximately 165,000 package delivery vehicles. Workhorse Group was one of the companies aiming to secure the NGDV contract, worth approximately $6.3 billion.

On February 23, 2021, the USPS issued a press release announcing that Oshkosh Defense had won the NGDV contract – not Workhorse Group.

On this news, Workhorse Group’s stock price fell $14.88 per share, or 47% to close at $16.47 on February 23, 2021. The price continued to fall in after-hours trading and opened on February 23, 2021, at $14/07, a drop of over 50% from the previous open.

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, and/or failed to disclose that: (1) the Company was merely hoping that USPS was going to select an electric vehicle as its Next Generation Delivery Vehicle, and had no assurance or indication from USPS that this was the case; (2) the Company had concealed the fact that electrifying the USPS’s entire fleet would be impractical and astronomically expensive; and (3) as a result, defendants’ statements about Workhorse Group’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

If you wish to serve as lead plaintiff, you must move the Court no later than May 7, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

If you purchased Workhorse Group securities, and/or would like to discuss your legal rights and options please visit https://www.bernlieb.com/cases/workhorsegroupinc-wkhs-shareholder-class-action-lawsuit-fraud-stock-376/apply/ or contact Matthew E. Guarnero toll free at (877) 779-1414 or [email protected]

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2021 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information

Matthew E. Guarnero
Bernstein Liebhard LLP
https://www.bernlieb.com
(877) 779-1414
[email protected]